Temmune Therapeutics SA
Temmune Therapeutics reported total assets of €3.43m at the end of the 2025 financial year (annual accounts filed with the NBB on 07 Apr 2026).
The score of Temmune Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +775 % Total assets +1141 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Temmune Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Apr 2026
- Year ended 31 Dec 2024filed on 18 Jul 2025
- Year ended 31 Dec 2023filed on 26 Mar 2024
- Year ended 31 Dec 2022filed on 28 Jun 2023
Temmune Therapeutics's financial analysis
- Solvency58.6%sector median: 50.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Temmune Therapeutics
Temmune Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0776.938.722
- VAT number
- BE0776938722
- Peppol
- Registered · 0208:0776938722 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 08 Nov 2021
- Registered office
- 2800 Mechelen
- Latest accounts
- 2025 · filed on 07 Apr 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Temmune Therapeutics (SA) has been based in Mechelen since 2021, active in: manufacture of medicaments. For 2025, it reports a net loss of €2.21m and equity of €2.01m; its revenue is not published. Its solvency stands at 58.6%, above the median of its sector (50.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Temmune Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Spica Therapeutics Research and experimental development on natural sciences and engineering Antwerp · balance sheet €7.45m
- Galenicap Manufacture of basic pharmaceutical products Ixelles · balance sheet €1.47m
- Simabs Manufacture of pharmaceutical preparations Diepenbeek · balance sheet €2.67m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- Pharma Chemicals France Manufacture of basic pharmaceutical products Braine-le-Château · balance sheet €1.08m
- SECOYA Technologies Manufacture of basic pharmaceutical products Ottignies-Louvain-la-Neuve · balance sheet €2.31m
- Asterion Research & Development Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.31m
Frequently asked questions about Temmune Therapeutics
What is the revenue of Temmune Therapeutics?
Temmune Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Temmune Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0776938722 for Temmune Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0776.938.722.
Where is the registered office of Temmune Therapeutics?
According to the CBE register, the registered office of Temmune Therapeutics is in 2800 Mechelen.
What is the equity of Temmune Therapeutics?
At the close of the 2025 financial year, the equity of Temmune Therapeutics amounts to 2,013,866 €, a solvency of 58.6% of total assets.
Who manages Temmune Therapeutics?
The register lists 8 active mandates at Temmune Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Temmune Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →